Similarly, the PSMA-DC trial (NCT05939414) targets patients with oligometastatic PCa, aiming to delay disease progression and defer initiation of ADT through early use of PSMA-targeted RLT following stereotactic body radiation therapy. Here, FOLH1 is linked to posterior cortical atrophy.